Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
September 13, 2024 06:45 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
September 12, 2024 08:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
September 03, 2024 07:08 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the closing of a new credit facility agreement with Oak Hill Advisors for a term loan of...
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
August 30, 2024 08:16 ET
|
Emergent BioSolutions
For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on opioid risks and how to be prepared with NARCAN® Nasal SprayIn recognition of...
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
August 29, 2024 18:53 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics...
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
August 20, 2024 11:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate...
Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
August 19, 2024 17:10 ET
|
Emergent BioSolutions
Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission50,000 doses of ACAM2000®, (Smallpox...
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
August 06, 2024 17:01 ET
|
Emergent BioSolutions
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance ...
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
August 06, 2024 08:00 ET
|
Emergent BioSolutions
Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE)...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
July 31, 2024 08:53 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a...